Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
Identifieur interne : 000007 ( PubMed/Corpus ); précédent : 000006; suivant : 000008Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
Auteurs : M. Rondy ; J. Castilla ; O. Launay ; S. Costanzo ; C. Ezpeleta ; F. Galtier ; K. De Gaetano Donati ; A. MorenSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Abstract
We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.
DOI: 10.1080/21645515.2015.1126013
PubMed: 27065000
Links to Exploration step
pubmed:27065000Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</title><author><name sortKey="Rondy, M" sort="Rondy, M" uniqKey="Rondy M" first="M" last="Rondy">M. Rondy</name><affiliation><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation></affiliation></author><author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name><affiliation><nlm:affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name><affiliation><nlm:affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</nlm:affiliation></affiliation></author><author><name sortKey="Costanzo, S" sort="Costanzo, S" uniqKey="Costanzo S" first="S" last="Costanzo">S. Costanzo</name><affiliation><nlm:affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ezpeleta, C" sort="Ezpeleta, C" uniqKey="Ezpeleta C" first="C" last="Ezpeleta">C. Ezpeleta</name><affiliation><nlm:affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Galtier, F" sort="Galtier, F" uniqKey="Galtier F" first="F" last="Galtier">F. Galtier</name><affiliation><nlm:affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</nlm:affiliation></affiliation></author><author><name sortKey="De Gaetano Donati, K" sort="De Gaetano Donati, K" uniqKey="De Gaetano Donati K" first="K" last="De Gaetano Donati">K. De Gaetano Donati</name><affiliation><nlm:affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</nlm:affiliation></affiliation></author><author><name sortKey="Moren, A" sort="Moren, A" uniqKey="Moren A" first="A" last="Moren">A. Moren</name><affiliation><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="doi">10.1080/21645515.2015.1126013</idno><idno type="RBID">pubmed:27065000</idno><idno type="pmid">27065000</idno><idno type="wicri:Area/PubMed/Corpus">000007</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</title><author><name sortKey="Rondy, M" sort="Rondy, M" uniqKey="Rondy M" first="M" last="Rondy">M. Rondy</name><affiliation><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation></affiliation></author><author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name><affiliation><nlm:affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Launay, O" sort="Launay, O" uniqKey="Launay O" first="O" last="Launay">O. Launay</name><affiliation><nlm:affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</nlm:affiliation></affiliation></author><author><name sortKey="Costanzo, S" sort="Costanzo, S" uniqKey="Costanzo S" first="S" last="Costanzo">S. Costanzo</name><affiliation><nlm:affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ezpeleta, C" sort="Ezpeleta, C" uniqKey="Ezpeleta C" first="C" last="Ezpeleta">C. Ezpeleta</name><affiliation><nlm:affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Galtier, F" sort="Galtier, F" uniqKey="Galtier F" first="F" last="Galtier">F. Galtier</name><affiliation><nlm:affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</nlm:affiliation></affiliation></author><author><name sortKey="De Gaetano Donati, K" sort="De Gaetano Donati, K" uniqKey="De Gaetano Donati K" first="K" last="De Gaetano Donati">K. De Gaetano Donati</name><affiliation><nlm:affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</nlm:affiliation></affiliation></author><author><name sortKey="Moren, A" sort="Moren, A" uniqKey="Moren A" first="A" last="Moren">A. Moren</name><affiliation><nlm:affiliation>a Epicon0063ept , Paris , France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27065000</PMID><DateCreated><Year>2016</Year><Month>4</Month><Day>11</Day></DateCreated><DateRevised><Year>2016</Year><Month>4</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2016</Year><Month>Feb</Month><Day>2</Day></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText NlmCategory="UNASSIGNED">We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.</AbstractText></Abstract><AuthorList><Author><LastName>Rondy</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Epicon0063ept , Paris , France.</Affiliation></AffiliationInfo></Author><Author><LastName>Castilla</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>b Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.</Affiliation></AffiliationInfo></Author><Author><LastName>Launay</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>c Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.</Affiliation></AffiliationInfo></Author><Author><LastName>Costanzo</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>d Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.</Affiliation></AffiliationInfo></Author><Author><LastName>Ezpeleta</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>e Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.</Affiliation></AffiliationInfo></Author><Author><LastName>Galtier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>f CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.</Affiliation></AffiliationInfo></Author><Author><LastName>de Gaetano Donati</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>g Department of Infectious Disease , Catholic University , Rome , Italy .</Affiliation></AffiliationInfo></Author><Author><LastName>Moren</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Epicon0063ept , Paris , France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ENG</Language><PublicationTypeList><PublicationType UI="">JOURNAL ARTICLE</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>2</Month><Day>2</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Influenza vaccine</Keyword><Keyword MajorTopicYN="N">case control studies</Keyword><Keyword MajorTopicYN="N">hospital</Keyword><Keyword MajorTopicYN="N">multicentre studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1126013</ArticleId><ArticleId IdType="pubmed">27065000</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27065000
|texte= Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27065000" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |